ECSP11011048A - Inhibidores de cinasa akt y p70 s6 - Google Patents

Inhibidores de cinasa akt y p70 s6

Info

Publication number
ECSP11011048A
ECSP11011048A EC2011011048A ECSP11011048A ECSP11011048A EC SP11011048 A ECSP11011048 A EC SP11011048A EC 2011011048 A EC2011011048 A EC 2011011048A EC SP11011048 A ECSP11011048 A EC SP11011048A EC SP11011048 A ECSP11011048 A EC SP11011048A
Authority
EC
Ecuador
Prior art keywords
formula
kinase inhibitors
akt
compounds
present
Prior art date
Application number
EC2011011048A
Other languages
English (en)
Spanish (es)
Inventor
Robert Dean Dally
Timothy Alan Shepherd
Sajan Joseph
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP11011048A publication Critical patent/ECSP11011048A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EC2011011048A 2008-11-11 2011-05-11 Inhibidores de cinasa akt y p70 s6 ECSP11011048A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
ECSP11011048A true ECSP11011048A (es) 2011-06-30

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011048A ECSP11011048A (es) 2008-11-11 2011-05-11 Inhibidores de cinasa akt y p70 s6

Country Status (36)

Country Link
US (1) US8148387B2 (OSRAM)
EP (1) EP2358710B1 (OSRAM)
JP (1) JP5432275B2 (OSRAM)
KR (1) KR101334460B1 (OSRAM)
CN (1) CN102216302B (OSRAM)
AR (1) AR074072A1 (OSRAM)
AU (1) AU2009314324B2 (OSRAM)
BR (1) BRPI0921916A2 (OSRAM)
CA (1) CA2743019C (OSRAM)
CO (1) CO6382114A2 (OSRAM)
CR (1) CR20110240A (OSRAM)
CY (1) CY1113409T1 (OSRAM)
DK (1) DK2358710T3 (OSRAM)
DO (1) DOP2011000129A (OSRAM)
EA (1) EA018947B1 (OSRAM)
EC (1) ECSP11011048A (OSRAM)
ES (1) ES2391704T3 (OSRAM)
HN (1) HN2011001247A (OSRAM)
HR (1) HRP20120738T1 (OSRAM)
IL (1) IL211940A (OSRAM)
JO (1) JO2822B1 (OSRAM)
MA (1) MA32776B1 (OSRAM)
MX (1) MX2011005000A (OSRAM)
MY (1) MY161461A (OSRAM)
NZ (1) NZ592062A (OSRAM)
PA (1) PA8846901A1 (OSRAM)
PE (1) PE20110807A1 (OSRAM)
PL (1) PL2358710T3 (OSRAM)
PT (1) PT2358710E (OSRAM)
RS (1) RS52520B (OSRAM)
SI (1) SI2358710T1 (OSRAM)
TN (1) TN2011000207A1 (OSRAM)
TW (1) TWI422587B (OSRAM)
UA (1) UA100190C2 (OSRAM)
WO (1) WO2010056563A1 (OSRAM)
ZA (1) ZA201102549B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5680638B2 (ja) 2009-07-02 2015-03-04 サノフイ 新規な(6−オキソ−1,6−ジヒドロピリミジン−2−イル)アミド誘導体、この調製およびakt(pkb)リン酸化インヒビターとしてのこの医薬的な使用
EP2491032B1 (en) 2009-10-23 2014-04-16 Eli Lilly and Company Akt inhibitors
JP5906303B2 (ja) 2011-04-07 2016-04-20 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH Aktキナーゼ阻害剤としてのイミダゾピリダジン類
EP2730575B1 (en) * 2011-07-09 2015-09-16 Xuanzhu Pharma Co., Ltd. Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof
US9145392B2 (en) 2011-09-12 2015-09-29 Merck Patent Gmbh Imidazole amines as modulators of kinase activity
BR112014005468A2 (pt) 2011-09-12 2017-03-21 Merck Patent Gmbh derivados de aminopiridina para uso como moduladores de atividade quinase
JP6280130B2 (ja) * 2012-11-16 2018-02-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体
ES2620119T3 (es) * 2012-11-16 2017-06-27 Merck Patent Gmbh Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa
MX370448B (es) * 2013-03-11 2019-12-13 Merck Patent Gmbh Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa.
RU2690679C2 (ru) * 2014-02-11 2019-06-05 Мерк Патент Гмбх Новые пиримидинимидазоламины в качестве модуляторов активности киназы
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
JP6576553B2 (ja) * 2016-05-20 2019-09-18 大鵬薬品工業株式会社 新規5H−ピロロ[2,3−d]ピリミジン−6(7H)−オン誘導体
AU2021238799A1 (en) * 2020-03-17 2022-09-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused bicyclic derivative, preparation method therefor, and pharmaceutical use thereof
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
WO2023041061A1 (zh) 2021-09-17 2023-03-23 江苏恒瑞医药股份有限公司 一种稠合二环类衍生物的可药用盐、晶型及其制备方法
JPWO2024009977A1 (OSRAM) * 2022-07-05 2024-01-11

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス, インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
SI2358710T1 (sl) 2012-11-30
MX2011005000A (es) 2011-05-25
CO6382114A2 (es) 2012-02-15
ZA201102549B (en) 2012-09-26
PE20110807A1 (es) 2011-10-31
CA2743019C (en) 2013-08-13
KR101334460B1 (ko) 2013-12-02
PT2358710E (pt) 2012-10-01
JP2012508274A (ja) 2012-04-05
HK1158203A1 (en) 2012-07-13
IL211940A (en) 2014-01-30
CN102216302B (zh) 2013-08-21
EP2358710A1 (en) 2011-08-24
AR074072A1 (es) 2010-12-22
KR20110074578A (ko) 2011-06-30
US8148387B2 (en) 2012-04-03
MY161461A (en) 2017-04-14
UA100190C2 (en) 2012-11-26
NZ592062A (en) 2013-03-28
JP5432275B2 (ja) 2014-03-05
MA32776B1 (fr) 2011-11-01
JO2822B1 (en) 2014-09-15
TWI422587B (zh) 2014-01-11
EA018947B1 (ru) 2013-11-29
US20100120801A1 (en) 2010-05-13
CY1113409T1 (el) 2016-06-22
CN102216302A (zh) 2011-10-12
TN2011000207A1 (en) 2012-12-17
RS52520B (sr) 2013-04-30
AU2009314324A1 (en) 2010-05-20
CA2743019A1 (en) 2010-05-20
EP2358710B1 (en) 2012-08-15
DK2358710T3 (da) 2012-09-03
PL2358710T3 (pl) 2012-12-31
CR20110240A (es) 2011-06-09
TW201022268A (en) 2010-06-16
AU2009314324B2 (en) 2013-06-20
ES2391704T3 (es) 2012-11-29
HN2011001247A (es) 2013-05-20
EA201170680A1 (ru) 2011-12-30
IL211940A0 (en) 2011-06-30
WO2010056563A1 (en) 2010-05-20
HRP20120738T1 (hr) 2012-10-31
PA8846901A1 (es) 2010-06-28
DOP2011000129A (es) 2016-02-29
BRPI0921916A2 (pt) 2015-12-29

Similar Documents

Publication Publication Date Title
ECSP11011048A (es) Inhibidores de cinasa akt y p70 s6
BR112012011328A2 (pt) inibidores de akt
ECSP099721A (es) Inhibidores de cinasa p70 s6
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CR20140544A (es) Compuestos para inhibir la progresión mitotica
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
GEP20227397B (en) Inhibitors of influenza viruses replication
CR11793A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
TN2010000131A1 (en) Polo-like kinase inhibitors
MX341849B (es) Nitrilos espirociclicos como inhibidores de proteasa.
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
BRPI0909737A2 (pt) compostos de pirrolidinila, composição farmacêutica compreendendo os mesmos e usos dos mesmos
GT200600117A (es) Nuevos compuestos farmaceuticos
CR11601A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201000703A1 (ru) Производные пиразола в качестве ингибиторов 5-lo
CL2011000292A1 (es) Compuestos derivados de enfumafungina y sus sales farmaceuticamente aceptables, como inhibidores de (1,3)-beta-d-glucano sintasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
UY32360A (es) Compuestos de etanamina y métodos de utilización de los mismos 545
UA99739C2 (ru) Ингибиторы polo-подобных киназ
CU23957B1 (es) Derivados de tiazolidin-2,4-diona